Cisplatin and Alternating Temozolomide in Recurrent High-Grade Gliomas: Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase II Clinical Trial
Xiaojie Ding, Di Chen, Zhenyu Zhang, Ying Qi, Dikang Chen, Jianbo Wen, Yuyuan Wang, Haixia Cheng, Chunxia Ji, Lingchao Chen, Chao Tang, Yu YaoBackground:
To evaluate the efficacy and safety of cisplatin combined with alternating temozolomide (TMZ) for recurrent high-grade glioma, as current treatments lack standardized protocols and predictive markers.
Methods:
This study evaluated cisplatin (20 mg/m 2 IV, days 1-3) and TMZ (125 mg/m 2 orally, days 1-7 and 15-21) in 35 patients, using the RANO criteria with 6-month progression-free survival (PFS-6) as the primary endpoint. The Kaplan-Meier analysis was applied for survival, and tumor molecular profiles were retrospectively assessed.
Results:
A median follow-up time was 61.2 months. The PFS-6 rate was 45.2%, and the median time to progression was 5.07 months. Four patients showed partial response, 16 had stable disease, and 11 had disease progression, with predominantly grade I to II toxicities. Low CD8+ tumor-infiltrating lymphocytes (TILs) correlated with improved disease control ( P = .031). Data from the CGGA showed that low CD8+ TILs were associated with better survival, while high CD8+ TILs indicated increased immune response and higher immune checkpoint expression, including programmed death 1 (PD-1).
Conclusions:
The cisplatin plus alternating TMZ regimen is feasible and safe for recurrent high-grade gliomas, with low CD8+ TILs potentially predicting favorable responses.